Search

Summary: Nodal peripheral T‐cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL‐TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL not otherwise specified (PTCL‐NOS) and angioimmunoblastic T‐cell lymphoma (AITL). This retrospective observational study included 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites. Patient diagnosis was centrally reviewed, and patients were reclassified according to the World Health Organization (WHO) 2016 criteria: 21 patients as PTCL‐NOS, 55 as AITL and 23 as PTCL‐TFH. Median follow‐up was 56.07 months (95% CI 38.7–73.4). Progression‐free survival (PFS) and overall survival (OS) were significantly higher in patients with PTCL‐TFH than in those with PTCL‐NOS and AITL (PFS, 24.6 months vs. 4.6 and 7.8 months, respectively, p = 0.002; OS, 52.6 months vs. 10.0 and 19.3 months, respectively, p < 0.001). Histological diagnosis maintained an independent influence on both PFS (hazard ratio [HR] 4.1 vs. PTCL‐NOS, p = 0.008; HR 2.6 vs. AITL, p = 0.047) and OS (HR 5.7 vs. PTCL‐NOS, p = 0.004; HR 2.6 vs. AITL, p = 0.096), regardless of the International Prognostic Index. These results suggest that PTCL‐TFH could have more favourable features and prognosis than the other PTCL subtypes, although larger series are needed to corroborate these findings. [ABSTRACT FROM AUTHOR]

Corticobasal degeneration (CBD) is a pathology of low incidence and prevalence worldwide; it is accompanied by symptoms such as dystonia, rigid akinetic syndrome (bradykinesia), gait disturbances, neurological deterioration associated with severe cortical subcortical atrophy, and progressive to moderate to severe neurocognitive deficits, especially in immediate verbal memory and dorsolateral or dysexecutive syndrome. We identified neurocognitive impairment and neuropsychiatric symptoms in a patient diagnosed with CBD. Participant was a 70-year-old female patient, single; she presented progressive memory loss of an immediate verbal nature. Initially, she was diagnosed with Alzheimer's disease and Lewy body dementia, finding that she had no characteristic signs and symptoms of these pathologies. The patient presented conciliation insomnia, gait disturbances, and severe neurocognitive deficit, especially in executive functions, immediate verbal memory, and visuospatial functioning. It was found that the patient presented neurocognitive alterations of the executive type (frontal lobe) such as decision making, planning, inhibition and operative memory, correlated with a severe alteration in her basic, instrumental and advanced activities of daily life, with a high risk factor for developing dementia. It is necessary to diagnose in an assertive and timely manner in order to generate functional neurorehabilitation plans in people diagnosed with CBD, with the main objective of positively impacting quality of life, at the individual, family, and social level. [ABSTRACT FROM AUTHOR]

Objective: Prostatic tumors are the most frequent malignant neoplasms in men, most of them being constituted by carcinomas; only 0.2% of malignant prostatic neoplasms are of mesenchimal origin. They are not well known, especially those of prostatic stromal phenotype., Methods and Results: We report the case of a 20 year-old man with a prostatic stromal sarcoma. After total cystoprostatectomy a tumor measuring 8 cm could be seen, replacing almost the whole prostate. Microscopically a spindle cell neoplasia with moderate atypia and a high mitotic index entrapping few elongated prostatic ducts (adopting a phyllodes tumor morphology) was observed., Conclusion: The clinical behavior of these infrequent sarcomas is not well-established. Recurrences are not uncommon whereas lung and bone metastases have been described. Twelve months after surgery our patient is alive without evidence of disease.